In re Lidoderm Antitrust Litigation

Track this case

Case Number:

3:14-md-02521

Court:

California Northern

Nature of Suit:

Anti-Trust

Multi Party Litigation:

Class Action, Multi-district Litigation

Judge:

William H. Orrick

Firms

Companies

Government Agencies

Sectors & Industries:

February 21, 2017
Lidoderm Buyers, End Payors Win Cert. In Pay-For-Delay MDL

Purchasers of the Lidoderm pain patch won class certification in an antitrust multidistrict litigation against Endo Pharmaceuticals and others on Tuesday when a California federal judge found that both direct purchasers and end-payors proved common injuries with alleged delays of a generic version of the drug.
November 29, 2016
Lidoderm Buyers, Payors Near Cert. In Pay-For-Delay MDL

A California federal judge indicated Tuesday he's inclined to certify a putative class of indirect drug buyers and a class of end-payors in a pay-for-delay multidistrict litigation against Endo Pharmaceuticals and others over the Lidoderm pain relief patch, saying that although the process of apportioning damages might be complex, that's not a reason to deny certification.
October 04, 2016
FTC Warns Against Endo Privilege Request In Lidoderm MDL

The Federal Trade Commission on Monday said a California federal judge should not allow Endo Pharmaceuticals to selectively waive its privilege in pay-for-delay multidistrict litigation over the Lidoderm pain relief patch, saying it could adversely affect the interests of the U.S. government.
April 19, 2016
Endo, Others Denied Wholesale Info In Pay-For-Delay MDL

Drug retailers suing Endo Pharmaceuticals and others in pay-for-delay multidistrict litigation over the Lidoderm pain relief patch do not have to turn over their full supply contracts with wholesalers, at least for now, a California federal judge ruled Monday, saying that "downstream discovery" of that type is routinely denied.
November 25, 2015
Teikoku Loses Bid To Boot 12 Firms From Lidoderm MDL

A California federal judge on Wednesday refused to disqualify 12 law firms representing retailers in pay-for-delay multidistrict litigation over the Lidoderm pain relief patch, saying plaintiffs' attorneys' use of a privileged document mistakenly handed over by Japanese drugmaker Teikoku did not warrant disqualification.
November 11, 2015
Endo Has No Privilege To Withold SEC Drafts In Drug MDL

A California federal judge overseeing multidistrict pay-for-delay litigation against Endo Pharmaceuticals over its painkiller Lidoderm has said the company must hand over early drafts of a letter it sent the U.S. Securities and Exchange Commission, saying the drugmaker isn't entitled to attorney-client privilege.
November 05, 2015
Teikoku Backs Up Bid To DQ 12 Firms In Lidoderm MDL

Japanese drugmaker Teikoku doubled down Thursday on its bid to disqualify at least 12 law firms representing retailers in pay-for-delay multidistrict litigation over the drug Lidoderm for using a privileged document that was wrongly handed over, telling a California federal court it "should not hesitate" to toss the firms from the case.
October 29, 2015
Retailers Tell Court Not To DQ 12 Firms In Lidoderm MDL

Retailers in pay-for-delay multidistrict litigation over the drug Lidoderm pushed back against a bid by Japanese drugmaker Teikoku to disqualify at least 12 law firms representing them for using a privileged document that was wrongly handed over, telling a California federal court Wednesday that the document wasn't actually privileged at all.
October 15, 2015
Drugmaker Wants 12 Firms Booted From Pay-For-Delay MDL

Japanese drugmaker Teikoku on Wednesday asked a California federal court to disqualify 12 law firms representing retailers in antitrust litigation over the drug Lidoderm, saying the law firms "left their ethical obligations at the door" by capitalizing on a privileged email that was mistakenly handed to them.
July 20, 2015
Retailers' Claims Trimmed In Lidoderm Pay-For-Delay Case

A California federal judge on Friday struck certain antitrust claims Walgreen Co. and other indirect purchasers of pain medication Lidoderm brought in a pay-for-delay case against Endo Pharmaceuticals, though he has given the grocery stores chains a chance to amend their complaint.